La vendita allo scoperto per Lexaria Bioscience dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Lexaria Bioscience. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Lexaria Bioscience (NASDAQ:LEXX) Azioni, Report sulle vendite allo scoperto

Lexaria Bioscience

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.

Lexaria Bioscience Corp

<a href="https://medium.com/@mingchikuo/vishay-the-hidden-key-winner-in-nvidias-ai-servers-and-rtx-50-series-supply-chain-vishay-3-0-526aec187854">https://medium.com/@mingchikuo/vishay-the-hidden-key-winner-in-nvidias-ai-servers-and-rtx-50-series-supply-chain-vishay-3-0-526aec187854</a>
<ol>
<li>While the tech industry focuses on Nvidia's AI server and RTX 50 series supply chain, my latest research reveals Vishay as the hidden key winner.</li>
<li>Vishay has secured better-than-expected orders for Nvidia's Blackwell AI servers (GB200 series and DGX/HGX B200) and RTX 50 series graphics cards. The component orders include MOSFET/DrMOS (VRPower), vPolyTan (Polymer Tantalum, such as T55), Current Shunt Resistors, Transient Voltage Suppressors (TVS), and Schottky Barrier Diodes (SBD), etc.</li>
<li>Among the components above, MOSFET and vPolyTan deserve special attention.</li>
<li>For GB200 NVL72/36's 8kW 54V-to-12V power supply, Nvidia has switched to a Renesas (controller) and Vishay (MOSFET) combination, replacing power management modules from Flextronics and Delta. Notably, Vishay has replaced Infineon as the current MOSFET supplier.</li>
<li>For DGX/HGX's 2kW 54V-to-12V power supply, Nvidia now uses ADI (controller) and Vishay (MOSFET), replacing MPS and Delta's power management modules.</li>
<li>The GB200 NVLink Switch's 2kW 54V-to-12V power supply also uses the Renesas (controller) and Vishay (MOSFET) combination.</li>
<li>For Nvidia's upcoming RTX 50 series graphics cards planned for 2025, Vishay has been selected as a new DrMOS supplier, with mass production starting in 1Q25.</li>
<li>Based on the above 4, 5, 6, and 7, Vishay's current MOSFET production capacity in 2025 is fully loaded, and it is expected to contribute approximately 20–30% of revenue, with a higher-than-average gross profit margin.</li>
<li>GB200 heavily utilizes Vishay's vPolyTan (polymer tantalum capacitors, primarily T55). Vishay's vPolyTan is already facing supply shortages for 2025 and is expected to contribute a high single-digit percentage of revenue with significantly above-average gross margins.</li>
<li>Vishay 3.0 stands to capitalize on robust demand for Nvidia's AI servers and the new RTX 50 series, with meaningful results anticipated in 2025. The company is also well-positioned to benefit from the automotive sector's rebound and the burgeoning IoT market. Looking ahead, Vishay's growth trajectory appears strong, driven by the ongoing success of its Vishay 3.0 strategy implementation.</li>
</ol>

News

NVDA

Analyst-Ming Chi Kuo Says "Vishay: The Hidden Key Winner in Nvidia's AI Servers and RTX 50 Series Supply Chain; Vishay 3.0 Strategy Shows Promise and Drives Robust Growth From 2025 Onward" - Medium

Buybacks

CLST

Catalyst Bancorp Approves Fifth Share Repurchase Program To Purchase Up To 215,000 Shares

French telecom company Orange announced its partnership with OpenAI, backed by Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), <a href="https://www.benzinga.com/topic/facebook">Facebook&#8217;s parent company</a>. 
This collaboration aims to create custom artificial intelligence (AI) models tailored to understand African regional languages better, starting with West Africa. These AI systems will be built upon open-source models, Whisper and Llama, to address the challenges of less represented languages in mainstream AI solutions.
Also Read: <a href="https://www.benzinga.com/24/11/42190381/analog-devices-q4-earnings-beats-estimates-automotive-rebound-outlook" target="_blank" rel="noreferrer noopener">Analog Devices Q4 Earnings: Beats Estimates, Automotive Rebound, Cautiously Optimistic Outlook &amp; More</a>
The project highlights the difficulties major AI firms face when their systems rely predominantly on U.S.-based data, which limits their ability to interpret languages and contexts from regions like Africa, the Middle East, and Europe. Orange plans to fine-tune these models by integrating language-specific data, improving their capacity to recognize and process regional dialects, CNBC <a target="_blank" href="https://www.cnbc.com/2024/11/26/orange-partners-with-openai-meta-on-custom-african-language-ai-models.html" rel="noreferrer noopener">reports</a>.
Orange&#8217;s initiative will begin by including two West African languages, Wolof and Pulaar, spoken by approximately 16 million and 6 million people, respectively. These languages are commonly used in Senegal, The Gambia, and Mauritania. The AI models will initially roll out in early 2025, with plans to cover all 18 West African nations in future expansions. Orange will also make these models available for non-commercial uses, including public health and education.
The initiative aligns with the growing global emphasis on &#8220;sovereign AI,&#8221; which focuses on creating regionally controlled AI systems to safeguard local languages, cultures, and data. Orange is also working on hosting OpenAI models in European data centers to ensure localized data processing and early access to advanced AI models. These efforts will help Orange develop innovative applications like AI-powered voice systems for customer service.
Nvidia chief Jensen Huang expressed <a target="_blank" href="https://www.benzinga.com/news/24/10/41220759/nvidia-ceo-jensen-huang-once-spoke-about-the-importance-of-every-country-needing-a-sovereign-ai-but" rel="noreferrer noopener">solidarity with sovereign AI</a>, which he deems critical for countries to leverage their strengths. He is backing it with a $110 million fund for startups.
International Business Machines Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) chief&nbsp;Arvind Krishna&nbsp;and Nvidia CFO&nbsp;Colette Kressexpressed similar opinions.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42186138/taiwan-semis-growth-fuels-us-rise-to-second-in-chipmaking" target="_blank" rel="noreferrer noopener">Taiwan Semi&#8217;s Growth Fuels US Rise To Second In Chipmaking: Report</a></li>
</ul>
Image: Pixabay

Tech

Media

MSFT

Meta, OpenAI, Orange Join Forces To Build AI Models For African Languages

Citigroup analyst Scott Gruber maintains APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Neutral and lowers the price target from $29 to $24.

Price Target

Analyst Ratings

Citigroup Maintains Neutral on APA, Lowers Price Target to $24

Citigroup analyst Yigal Nochomovitz maintains Caribou Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBU#NASDAQ">CRBU</a>) with a Buy and lowers the price target from $30 to $6.

CRBU

Citigroup Maintains Buy on Caribou Biosciences, Lowers Price Target to $6

MoffettNathanson analyst Michael Morton maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and raises the price target from $235 to $248.

AMZN

MoffettNathanson Maintains Buy on Amazon.com, Raises Price Target to $248

FACTU

Trading Halt: Halt status updated at 10:35:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) has certainly had its share of ups and downs lately, and right now, it&#8217;s riding a <a href="https://www.benzinga.com/topic/amd">significant bearish wave.</a>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091001/Screenshot-2024-11-26-at-6.11.41-PM.png" alt="" class="wp-image-665522" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091001/Screenshot-2024-11-26-at-6.11.41-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091001/Screenshot-2024-11-26-at-6.11.41-PM-300x234.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112624&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
<h2 class="wp-block-heading">AMD Stock: Bearish Momentum Takes Hold</h2>
At $142.68, AMD&#8217;s stock price is well below its five-day, 20-day and 50-day exponential moving averages (EMAs), signaling a continuation of the downward trend. With the 20-day simple moving average (SMA) doing a tango with the stock at $141.97 and the 50-day SMA farther above at $153.29, it&#8217;s clear that the stock&#8217;s momentum is still on the decline. 
Also, AMD stock is trading well under its 200-day SMA of $160.23, signaling long-term bearish pressure.
Read Also: <a href="https://www.benzinga.com/24/11/42186138/taiwan-semis-growth-fuels-us-rise-to-second-in-chipmaking">Taiwan Semi&#8217;s Growth Fuels US Rise To Second In Chipmaking: Report</a>
<h2 class="wp-block-heading">A Glimmer Of Hope For AMD Stock Investors</h2>
But don&#8217;t put AMD on your &#8220;avoid&#8221; list just yet. There's a flicker of hope on the short-term horizon. The eight-day SMA at $138.81 offers a tiny bullish glimmer, suggesting a possible rebound. 
However, the relative strength index (RSI) of 46.42 is firmly in neutral territory—neither oversold nor overbought—leaving plenty of room for either a stabilizing move or continued decline.
<h2 class="wp-block-heading">Technical Indicators Still Weighing Down AMD Stock</h2>
Despite these flickering signals of hope, the broader technical indicators aren't kind to AMD. The moving average convergence/divergence (MACD) at a negative 3.81 reinforces the prevailing bearish momentum. Unless a substantial catalyst turns things around, the stock will need more than a light breeze to lift it out of its slump.
<h2 class="wp-block-heading">AMD&#8217;s Market Share Gains: Temporary Or Sustainable?</h2>
AMD&#8217;s latest third-quarter market share <a href="https://www.gurufocus.com/news/2615820/amd-gains-market-share-in-q3-despite-challenges-in-server-cpu-sector?r=4bf001661e6fdd88d0cd7a5659ff9748&amp;mod=news_archive">gains</a>—particularly in the notebook and desktop markets—are promising, but are they sustainable? The company saw its desktop market share increase by 6% to 28.7%, and its revenue share rise by 8%.
However, concerns persist over whether the surge is due to a temporary product clearing by Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), rather than a lasting shift in the competitive landscape.
As AMD continues to push ahead with its <a href="https://www.benzinga.com/24/11/42166116/amd-boosts-india-investments-400-million-pledged-supercomputers-in-the-works">$400 million R&amp;D investment in India</a> and explores new avenues in AI, investors might want to keep an eye on the technicals. 
If the bearish trend continues, AMD may need more than just market share gains to reverse its current trajectory.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42180029/ark-invest-shakes-up-portfolio-with-big-tesla-and-amazon-trades">Cathie Wood-Led Ark Invest&#8217;s Latest Portfolio Maneuver: Dumps Tesla And Palantir Shares, Buys Amazon And AMD Stock</a></li>
</ul>
Photo: Shutterstock

Technicals

Trading Ideas

INTC

AMD Struggles Below Critical Levels: Can Market Share Growth Turn The Tide?

WIIM

MRNA

Moderna shares are trading lower after JP Morgan maintained an Underweight rating on the stock and lowered its price target from $59 to $45.

NRG Energy shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $93 to $113.

Investors with a lot of money to spend have taken a bullish stance on Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ACHR, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 13 uncommon options trades for Archer Aviation.
This isn't normal.
The overall sentiment of these big-money traders is split between 76% bullish and 15%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $91,251, and 11 are calls, for a total amount of $386,385.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $2.0 and $10.0 for Archer Aviation, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Archer Aviation's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Archer Aviation's whale activity within a strike price range from $2.0 to $10.0 in the last 30 days. 
<h3>Archer Aviation Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732635071_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.25</td>
<td>$1.15</td>
<td>$1.2</td>
<td>$7.50</td>
<td>$61.2K</td>
<td>809</td>
<td align="right">530</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$2.8</td>
<td>$2.4</td>
<td>$2.8</td>
<td>$5.00</td>
<td>$56.0K</td>
<td>14.8K</td>
<td align="right">247</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$2.45</td>
<td>$2.35</td>
<td>$2.45</td>
<td>$5.00</td>
<td>$49.0K</td>
<td>2.0K</td>
<td align="right">204</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$2.15</td>
<td>$2.05</td>
<td>$2.15</td>
<td>$7.00</td>
<td>$42.9K</td>
<td>7.9K</td>
<td align="right">404</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$3.6</td>
<td>$3.3</td>
<td>$3.5</td>
<td>$7.00</td>
<td>$35.0K</td>
<td>4.1K</td>
<td align="right">64</td>
</tr>
</tbody>
</table>

<h3>About Archer Aviation</h3>
Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner.
Following our analysis of the options activities associated with Archer Aviation, we pivot to a closer look at the company's own performance.
<h3>Current Position of Archer Aviation</h3>
<ul>
<li>Currently trading with a volume of 14,382,830, the ACHR's price is down by -2.94%, now at $7.26. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 90 days.</li>
</ul>
<h3>What The Experts Say On Archer Aviation</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $11.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $11. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Archer Aviation with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

ACHR

Archer Aviation Unusual Options Activity For November 26

ARWR

Arrowhead Pharmaceuticals shares are trading higher after the company entered into a global licensing and collaboration agreement with Sarepta Therapeutics for multiple clinical and preclinical siRNA programs.

Investors with a lot of money to spend have taken a bearish stance on Celsius Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CELH, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Celsius Holdings.
This isn't normal.
The overall sentiment of these big-money traders is split between 26% bullish and 60%, bearish.
Out of all of the special options we uncovered, 9 are puts, for a total amount of $427,399, and 6 are calls, for a total amount of $570,597.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $15.0 to $130.0 for Celsius Holdings over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Celsius Holdings's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Celsius Holdings's substantial trades, within a strike price spectrum from $15.0 to $130.0 over the preceding 30 days.
<h3>Celsius Holdings Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732635066_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CELH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$16.8</td>
<td>$15.5</td>
<td>$15.76</td>
<td>$15.00</td>
<td>$220.6K</td>
<td>184</td>
<td align="right">140</td>
</tr>
<tr>
<td>CELH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$101.8</td>
<td>$101.3</td>
<td>$101.75</td>
<td>$130.00</td>
<td>$101.7K</td>
<td>200</td>
<td align="right">20</td>
</tr>
<tr>
<td>CELH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.55</td>
<td>$3.4</td>
<td>$3.55</td>
<td>$28.33</td>
<td>$97.6K</td>
<td>1.3K</td>
<td align="right">309</td>
</tr>
<tr>
<td>CELH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.65</td>
<td>$8.6</td>
<td>$8.6</td>
<td>$30.00</td>
<td>$86.0K</td>
<td>5.0K</td>
<td align="right">233</td>
</tr>
<tr>
<td>CELH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$8.8</td>
<td>$8.75</td>
<td>$8.8</td>
<td>$30.00</td>
<td>$84.4K</td>
<td>5.0K</td>
<td align="right">97</td>
</tr>
</tbody>
</table>

<h3>About Celsius Holdings</h3>
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 96% of revenue concentrated in North America. Celsius' products contain natural ingredients and a metabolism-enhancing formulation, appealing to fitness and active lifestyle enthusiasts. The firm's portfolio includes its namesake Celsius Originals beverages, Celsius Essentials line (containing aminos), and Celsius On-the-Go powder packets. Celsius dedicates its efforts to branding and innovation, while it utilizes third parties for the manufacturing, packaging, and distribution of its products. In 2022, Celsius forged a 20-year distribution agreement with PepsiCo, which holds an 8.5% stake in the business.
After a thorough review of the options trading surrounding Celsius Holdings, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Celsius Holdings's Current Market Status</h3>
<ul>
<li>With a volume of 1,720,788, the price of CELH is down -5.71% at $28.05. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 93 days.</li>
</ul>
<h3>What The Experts Say On Celsius Holdings</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $44.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from B. Riley Securities persists with their Buy rating on Celsius Holdings, maintaining a target price of $44. 
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Celsius Holdings, which currently sits at a price target of $45. 
&#x2A; An analyst from B. Riley Securities persists with their Buy rating on Celsius Holdings, maintaining a target price of $47. 
&#x2A; An analyst from Roth MKM has decided to maintain their Buy rating on Celsius Holdings, which currently sits at a price target of $40. 
&#x2A; An analyst from UBS persists with their Buy rating on Celsius Holdings, maintaining a target price of $45. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Celsius Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

CELH

Looking At Celsius Holdings's Recent Unusual Options Activity

Whales with a lot of money to spend have taken a noticeably bearish stance on Cava Group.
Looking at options history for Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 0% of the investors opened trades with bullish expectations and 60% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $159,975 and 7, calls, for a total amount of $260,023.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $80.0 to $200.0 for Cava Group during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Cava Group's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Cava Group's whale activity within a strike price range from $80.0 to $200.0 in the last 30 days. 
<h3>Cava Group Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732635061_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/18/26</td>
<td>$58.9</td>
<td>$57.6</td>
<td>$58.25</td>
<td>$120.00</td>
<td>$58.2K</td>
<td>85</td>
<td align="right">10</td>
</tr>
<tr>
<td>CAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$40.1</td>
<td>$37.0</td>
<td>$38.65</td>
<td>$160.00</td>
<td>$57.9K</td>
<td>61</td>
<td align="right">15</td>
</tr>
<tr>
<td>CAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$33.1</td>
<td>$23.1</td>
<td>$27.6</td>
<td>$160.00</td>
<td>$55.2K</td>
<td>27</td>
<td align="right">0</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$6.3</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$145.00</td>
<td>$55.1K</td>
<td>1.0K</td>
<td align="right">185</td>
</tr>
<tr>
<td>CAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$23.4</td>
<td>$23.4</td>
<td>$23.4</td>
<td>$160.00</td>
<td>$46.8K</td>
<td>7</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About Cava Group</h3>
Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates the majority of its revenue from the CAVA segment.
Following our analysis of the options activities associated with Cava Group, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Cava Group</h3>
<ul>
<li>With a trading volume of 306,516, the price of CAVA is down by -0.82%, reaching $141.37.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 91 days from now.</li>
</ul>
<h3>What The Experts Say On Cava Group</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $153.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from TD Cowen has decided to maintain their Buy rating on Cava Group, which currently sits at a price target of $150. 
&#x2A; An analyst from Stifel persists with their Buy rating on Cava Group, maintaining a target price of $175. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Neutral rating on Cava Group with a target price of $163. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Cava Group with a target price of $135. 
&#x2A; An analyst from Bernstein downgraded its action to Market Perform with a price target of $145. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cava Group options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

CAVA

Behind the Scenes of Cava Group's Latest Options Trends

SRPT

Sarepta Therapeutics shares are trading higher after the company announced a global licensing and collaboration agreement with Arrowhead Pharmaceuticals for multiple clinical and preclinical siRNA programs.

Chevron shares are trading higher after Citigroup upgraded the stock from Neutral to Buy and raised its price target from $145 to $185.

<a href="https://www.aiaaic.org/aiaaic-repository/ai-algorithmic-and-automation-incidents/ftc-investigates-evolv-for-misleading-marketing" title="https://www.aiaaic.org/aiaaic-repository/ai-algorithmic-and-automation-incidents/ftc-investigates-evolv-for-misleading-marketing">https://www.aiaaic.org/aiaaic-repository/ai-algorithmic-and-automation-incidents/ftc-investigates-evolv-for-misleading-marketing</a>

EVLV

'The U.S. FTC Is Investigating Weapons Screening Firm Evolv Technologies Over Claims It Made About Its AI Systems Accurately Identifying Weapons Passing Through Its Screeners' - AIAAIC

On Monday, Alector, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALEC#NASDAQ">ALEC</a>) released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42174676/alector-announces-results-from-al002-invoke-2-phase-2-trial-in-individuals-with-early-alzheimers-d" rel="noreferrer noopener">early Alzheimer&#8217;s disease (AD)</a>.
AL002 failed to meet the primary endpoint of slowing Alzheimer&#8217;s clinical progression as measured by the Clinical Dementia Rating Sum of Boxes (CDR-SB).
Also, no treatment effects favored AL002 on secondary clinical and functional endpoints.
The company says treatment with AL002 resulted in sustained target engagement and pharmacodynamic responses indicative of microglial activation.
Similarly, there were no significant effects on Alzheimer&#8217;s fluid biomarkers favoring AL002, and amyloid PET imaging demonstrated no treatment-related reduction of brain amyloid levels.
As previously reported, INVOKE-2 showed MRI changes resembling amyloid-related imaging abnormalities (ARIA) and infusion-related reactions. ARIA was primarily seen in participants treated with AL002.
Based on the results, Alector is stopping the long-term extension study.
Alector&#8217;s focus are progranulin-elevating programs, latozinemab, and AL101/GSK4527226, developed in collaboration with GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>).
Topline data from the pivotal INFRONT-3 Phase 3 trial of latozinemab in frontotemporal dementia with a progranulin gene mutation is expected in late 2025 or early 2026.
PROGRESS-AD Phase 2 trial of AL101/GSK4527226 in early AD reached over one-third of its target enrollment of 282 participants. Alector is also advancing its preclinical candidates aimed at a broad and diverse range of protein and enzyme targets.
To align resources with these strategic priorities, Alector is reducing its workforce by approximately 17%.
As of September 30, 2024, Alector has $457.2 million in cash, cash equivalents, and investments, which the company continues to expect will provide a runway through 2026.
William Blair expressed surprise and disappointment at the update, given the strong scientific basis, evidence of target engagement, and potential signs of disease modification tied to ARIA cases. The analyst maintained the <a target="_blank" href="https://www.benzinga.com/quote/ALEC/analyst-ratings" rel="noreferrer noopener">Outperform rating.</a>
Despite still seeing promise in TREM2 as a target and in neuroinflammatory modulation, the firm is removing AL002 from its model due to the study&#8217;s failure, underscoring the difficulties in developing treatments for neurodegenerative diseases.
The analyst also expects AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) to opt out of the program partnership and forgo the potential <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41786512/alector-reports-third-quarter-2024-financial-results-and-provides-business-update" rel="noreferrer noopener">$250 million licensing payment</a>.
AbbVie has an exclusive option to develop and commercialize AL002 globally.
Price Action: ALEC stock is down 37.3% at $2.485 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/42190068/roches-proposed-acquisition-of-poseida-therapeutics-poised-to-establish-new-core-capability-in-cell-therapy-for-cancer-and-autoimmune-diseases-details" target="_blank" rel="noreferrer noopener">Roche&#8217;s Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details</a></li>
</ul>
Image via Shutterstock.

Analyst Color

Biotech

Equities

Health Care

Reiteration

Movers

General

ABBV

ALEC

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

<a href="https://x.com/AvichayAdraee/status/1861428483966050423" title="https://x.com/AvichayAdraee/status/1861428483966050423">https://x.com/AvichayAdraee/status/1861428483966050423</a>

Macro Economic Events

Economics

iShares MSCI Israel Capped Investable Market Index Fund

Israeli Military Spokesman, Avichay Adraee, On X Issues Warning For Residents Near Hezbollah Facilities Targeted By IDF

Bernstein analyst Richard Clarke initiates coverage on Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) with a Outperform rating and announces Price Target of $290.

Initiation

Bernstein Initiates Coverage On Royal Caribbean Gr with Outperform Rating, Announces Price Target of $290

Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience is advancing its DehydraTECH drug delivery platform to compete in the booming ...

Lexaria Bioscience Enters GLP-1 Market Race

Lexaria Bioscience (LEXX) has received lead clinical site human research ethics committee approval that was required before dosing can begin in the...

Lexaria Bioscience receives HREC approval for Phase 1b DehydraTECH GLP-1 study

Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience has received ethics board approval for its 12-week Phase 1b GLP-1 study, which...

Lexaria Bioscience Advances GLP-1 Study

Lexaria Bioscience (LEXX) has engaged a contract research organization to perform the world's first-ever fluorescently tagged DehydraTECH-semagluti...

Lexaria Bioscience signs contract for DehydraTECH GLP-1 biodistribution study

Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience has initiated a groundbreaking study to explore the biodistribution of its Deh...

Lexaria Bioscience Launches Innovative Drug Study

Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience's DehydraTECH technology has shown promising results in a 12-week diabetes ani...

Lexaria Bioscience's DehydraTECH Outshines in Diabetes Study

Earnings week ahead: CRWD, DELL, ZM, WDAY, HPQ, M, BBY and more

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Lexaria Bioscience (LEXX – Research Report), with a price targe...

Lexaria Bioscience's Promising Developments and Ethics Board Approval Boost Buy Rating

Lexaria Bioscience (LEXX) announced that dosing has been completed for human pilot study #3 investigating a DehydraTECH-processed version of the du...

Lexaria Bioscience completes dosing for GLP-1 human pilot study #3

Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience has completed dosing in a human pilot study of its oral version of tirzepatide...

Comments

Lexaria Bioscience

Vendite allo scoperto

Lexaria Bioscience (NASDAQ:LEXX) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO